Hensley ML - Search Results

1

The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatment.

O'Cearbhaill R, Zhou Q, Iasonos A, Hensley ML, Tew WP, Aghajanian C, Spriggs DR, Lichtman SM, Sabbatini PJ. O'Cearbhaill R, et al. Among authors: hensley ml. Gynecol Oncol. 2010 Mar;116(3):326-31. doi: 10.1016/j.ygyno.2009.10.070. Epub 2009 Nov 27. Gynecol Oncol. 2010. PMID: 19944454 Free PMC article.

2

Phase II study of elsamitrucin (BMY-28090) for the treatment of patients with refractory/relapsed non-Hodgkin's lymphoma.

Allen SL, Schacter LP, Lichtman SM, Bukowski R, Fusco D, Hensley M, O'Dwyer P, Mittelman A, Rosenbloom B, Huybensz S. Allen SL, et al. Invest New Drugs. 1996;14(2):213-7. doi: 10.1007/BF00210793. Invest New Drugs. 1996. PMID: 8913843 Clinical Trial.

3

Implementation of disease management guidelines in patients with advanced ovarian cancer.

Hensley ML, Sabbatini P, Spriggs D. Hensley ML, et al. Semin Oncol. 1999 Feb;26(1 Suppl 1):46-51. Semin Oncol. 1999. PMID: 10071973 Review.

4

Paclitaxel-based chemotherapy in carcinoma of the fallopian tube.

Gemignani ML, Hensley ML, Cohen R, Venkatraman E, Saigo PE, Barakat RR. Gemignani ML, et al. Among authors: hensley ml. Gynecol Oncol. 2001 Jan;80(1):16-20. doi: 10.1006/gyno.2000.6012. Gynecol Oncol. 2001. PMID: 11136563 Clinical Trial.

5

Identification of risk factors for requiring transfusion during front-line chemotherapy for ovarian cancer.

Hensley ML, Lebeau D, Leon LF, Venkatraman E, Waltzman R, Sabbatini P, Almadrones L, Chi D, Spriggs D. Hensley ML, et al. Gynecol Oncol. 2001 Jun;81(3):485-9. doi: 10.1006/gyno.2001.6185. Gynecol Oncol. 2001. PMID: 11371143

6

The costs and efficacy of liposomal doxorubicin in platinum-refractory ovarian cancer in heavily pretreated patients.

Hensley ML, Hoppe B, Leon L, Sabbatini P, Aghajanian C, Chi D, Spriggs DR. Hensley ML, et al. Gynecol Oncol. 2001 Sep;82(3):464-9. doi: 10.1006/gyno.2001.6299. Gynecol Oncol. 2001. PMID: 11520141

7

Identification of prognostic factors in advanced epithelial ovarian carcinoma.

Chi DS, Liao JB, Leon LF, Venkatraman ES, Hensley ML, Bhaskaran D, Hoskins WJ. Chi DS, et al. Among authors: hensley ml. Gynecol Oncol. 2001 Sep;82(3):532-7. doi: 10.1006/gyno.2001.6328. Gynecol Oncol. 2001. PMID: 11520151

8

Intraperitoneal chemotherapy for ovarian carcinoma: results of long-term follow-up.

Barakat RR, Sabbatini P, Bhaskaran D, Revzin M, Smith A, Venkatraman E, Aghajanian C, Hensley M, Soignet S, Brown C, Soslow R, Markman M, Hoskins WJ, Spriggs D. Barakat RR, et al. J Clin Oncol. 2002 Feb 1;20(3):694-8. doi: 10.1200/JCO.2002.20.3.694. J Clin Oncol. 2002. PMID: 11821450

9

Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy.

Dizon DS, Sabbatini PJ, Aghajanian C, Hensley ML, Spriggs DR. Dizon DS, et al. Among authors: hensley ml. Gynecol Oncol. 2002 Mar;84(3):378-82. doi: 10.1006/gyno.2001.6519. Gynecol Oncol. 2002. PMID: 11855873

10

Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer.

Dizon DS, Hensley ML, Poynor EA, Sabbatini P, Aghajanian C, Hummer A, Venkatraman E, Spriggs DR. Dizon DS, et al. Among authors: hensley ml. J Clin Oncol. 2002 Mar 1;20(5):1238-47. doi: 10.1200/JCO.2002.20.5.1238. J Clin Oncol. 2002. PMID: 11870166

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

179 results

Search Page